Neuronetics, Inc. (STIM)

Executive Summary / Key Takeaways

• Vertical Integration Creates a Unique Mental Health Platform: The December 2024 acquisition of Greenbrook TMS transforms Neuronetics from a capital equipment vendor into the only vertically integrated TMS provider, combining proprietary device technology with a national care delivery network that generated $87M in clinic revenue in 2025 and is growing at double-digit rates.

• Cash Flow Inflection Signals Business Model Validation: Despite a 99% revenue surge to $149M and margin compression from 72% to 48%, the company achieved positive operating cash flow of $0.9M in Q4 2025, proving that clinic operations can generate self-sustaining cash while the legacy device business stabilizes.

• Adolescent Market Expansion Drives Next Growth Leg: FDA clearance for patients aged 15-21 makes NeuroStar the first CMS-approved treatment for this demographic, with adolescent new patient starts growing 25% in 2025 and a 2.6x increase among 15-17 year olds, opening a largely untapped $1B+ addressable market.

• Margin Dilution Is Temporary, Operational Leverage Is Emerging: The 24-percentage-point gross margin decline reflects a mix shift to lower-margin clinics, but Q4 2025 marked the highest quarterly margin of the year at 52%, and management expects 47-49% margins in 2026 as operational efficiencies and volume gains offset structural mix effects.

• Valuation Disconnect Offers Asymmetric Risk/Reward: Trading at $1.52 with an enterprise value of $167M (1.12x revenue), STIM trades at a fraction of profitable medtech peers like BrainsWay (BWAY) (9.2x revenue) and LivaNova (LIVN) (2.4x revenue), while offering superior pro forma growth and a clearer path to profitability than pharmaceutical competitor Axsome Therapeutics (AXSM).

Setting the Scene: From Device Maker to Integrated Mental Health Platform

Neuronetics, incorporated in Delaware in April 2003, spent its first two decades building a market-leading medical device business based on the principle that mental health deserves the same technological rigor as physical health. The NeuroStar Advanced Therapy System, its first commercial product, pioneered transcranial magnetic stimulation (TMS) for major depressive disorder, accumulating a large real-world outcomes dataset with 237,574 patients treated and over 8.5 million sessions delivered. This foundation created a durable moat in the TMS device market, where FDA clearances, reimbursement relationships, and clinical evidence form significant barriers to entry.

The company's June 2018 IPO at $17 per share valued a pure-play device story, but the December 2024 acquisition of Greenbrook TMS fundamentally rewrote the investment narrative. Greenbrook's 93 treatment centers and national referral network transformed Neuronetics into a vertically integrated mental health platform, capturing value across the entire care delivery chain. This strategic pivot addresses the limitation of the device-only model: while NeuroStar systems generate high-margin capital sales and recurring treatment session revenue, growth was previously constrained by psychiatrist adoption rates and capital budget cycles. The clinic segment now directly controls patient access, referral relationships, and treatment capacity, enabling faster scaling and deeper market penetration.

The mental health treatment landscape provides fertile ground for this integration. Depression affects over 21 million adults annually in the U.S., with treatment-resistant depression (TRD) representing a $30 billion economic burden. Traditional antidepressants fail 30-40% of patients, creating a clear medical need for non-invasive alternatives like TMS. The market structure favors integrated players who can navigate complex reimbursement, manage patient intake, and deliver consistent clinical outcomes. Neuronetics now sits at the center of this ecosystem, supplying both the technology and the delivery infrastructure, while competitors remain siloed as either device manufacturers or clinic operators.

Technology, Products, and Strategic Differentiation

Neuronetics' competitive moat rests on three pillars: proprietary NeuroStar technology, a large clinical dataset in TMS, and exclusive control over a national care delivery network. The NeuroStar system uses MRI-strength magnetic pulses to stimulate the left dorsolateral prefrontal cortex , the brain region most associated with mood regulation. Unlike competing TMS systems from BrainsWay, Magstim, or MagVenture, NeuroStar offers standardized protocols backed by extensive randomized controlled trials and real-world evidence, giving psychiatrists confidence in consistent patient outcomes.

The adolescent FDA clearance for patients aged 15-21, granted in March 2024, represents a critical technological and regulatory milestone. This makes NeuroStar the first CMS-approved treatment for depression in this demographic, opening access to over 5 million adolescent patients. The clinical data supporting this clearance—showing nearly 70% improvement rates in 1,200 patients aged 12-21 with less than 1% symptom worsening—provides payers and providers with the evidence needed to expand coverage. TRICARE West, EverNorth Health Services, Humana (HUM), and Aetna, owned by CVS Health (CVS), have already added coverage, with several Blue Cross Blue Shield entities following suit. Adolescent treatment represents a greenfield market where NeuroStar faces no entrenched competition, and the 2.6x growth in 15-17 year old patients in 2025 suggests rapid adoption is already underway.

The Better Me Provider (BMP) program demonstrates how technology translates into economic advantage. BMP sites, which meet strict patient responsiveness and educational standards, treat three times more patients per quarter than non-participating practices and respond to inquiries twice as fast. With over 420 active BMP sites and nearly 100 additional sites working toward qualification, this program creates a high-performance distribution channel. The Provider Connection Program, launched in Q2 2025, extends this advantage by educating primary care physicians—who manage 60% of depression cases but rarely refer for TMS—through over 400 educational meetings that generated 210 new referral sites by year-end. This builds a direct referral pipeline that bypasses traditional psychiatric gatekeepers, expanding the addressable market beyond the 40,000 U.S. psychiatrists to over 200,000 primary care physicians.

The Greenbrook acquisition adds operational capabilities that pure device companies lack. The Regional Account Manager (RAM) program completed over 47,000 physician outreach activities in 2025, adding 1,300 new referring providers. This direct sales engine, combined with AI-driven benefits investigation that achieves high first-pass claim acceptance rates, reduces referral-to-treatment friction and accelerates cash collection. In Q3 2025, Neuronetics collected more cash than it booked as revenue for the first time—a milestone that validates the integrated model's ability to manage complex reimbursement cycles.

Financial Performance & Segment Dynamics: Evidence of Strategic Execution

The 99% revenue surge to $149.2 million in 2025 reflects a significant segment transformation. Medical Device revenue declined 12% to $62.2 million, as the company realigned the capital sales team toward "TMS-ready" high-volume accounts. System shipments fell from 185 to 159 units, yet Q4 2025 showed a 15% pro forma increase in system revenue with 49 units shipped, maintaining an average selling price above $85,000 for the fourth consecutive quarter. This demonstrates pricing power in an increasingly competitive market while improving account quality—new customers now reach first patient treatment faster and generate higher lifetime value.

Treatment session revenue in the device segment declined 15% to $43.3 million, but this reflects the elimination of $8.2 million in intercompany sales to Greenbrook rather than underlying demand weakness. Pro forma treatment session utilization grew 11% in Q3 and 6% in Q4, with the full-year decline primarily attributable to customer inventory build in 2024 following Change Healthcare (UNH) cyber events. Management expects normalized inventory levels in 2026, which should restore reported growth to match utilization trends. This inventory dynamic is a temporary headwind that has obscured strong underlying demand.

The Clinic Services segment is the primary growth driver. Revenue rose from $4.4 million to $87 million, representing 59% of U.S. revenues, with pro forma growth of 28% for the full year and 37% in Q4. This growth is volume-driven: total treatment volume increased 18% year-over-year in Q4, while SPRAVATO treatments grew from 30% to 35% of total treatments. The shift toward Administer & Observe (A&O) billing —86% of SPRAVATO volume in Q3, up 300 basis points from Q2—optimizes profitability by avoiding drug costs and inventory risk. This optimization shows management is prioritizing margin over top-line growth, a discipline essential for achieving profitability.

Consolidated gross margin compression from 72.3% to 48.5% reflects the mix shift to clinics, which operate at approximately 30% gross margin versus NeuroStar's 74-75% standalone margin. However, Q4 2025 gross margin of 52% marked the highest quarterly level of the year, driven by efficiency gains in clinic operations and favorable product mix. This sequential improvement suggests the margin floor has been established and operational leverage will drive gradual expansion toward the 47-49% guided range for 2026. While absolute margin levels are lower, the clinic business offers superior revenue scalability and recurring cash generation.

Operating expenses increased 17% to $103.7 million, including $8.5 million in non-cash stock-based compensation and the full cost of Greenbrook's operations. More importantly, operating cash burn improved sequentially every quarter, from negative $17 million in Q1 to positive $0.9 million in Q4. This trajectory validates the realization of $23 million in annualized synergies from the acquisition, with the full benefit expected by Q3 2026. The Q4 cash flow inflection demonstrates that the integrated model can be self-funding, reducing reliance on external capital.

Outlook, Management Guidance, and Execution Risk

Management's 2026 guidance reveals a company at an operational inflection point. Revenue guidance of $160-166 million implies 9% growth at the midpoint, with clinic revenue growing in the double digits to mid-teens while NeuroStar grows in the low to mid-single digits. This confirms the integrated strategy is working—the clinic network is the primary growth engine while the device business stabilizes as a high-margin cash generator.

Gross margin guidance of 47-49% for 2026 suggests modest compression from Q4's 52% level, likely reflecting continued mix shift toward clinics and seasonal factors. However, efficiency efforts within Greenbrook clinics and optimized SPRAVATO billing are expected to support margin expansion over time. The key assumption is that clinic volume growth will leverage fixed infrastructure costs, improving segment margins from the current 30% level. This operational leverage determines whether the integrated model can eventually match the profitability of the legacy device business.

Operating expense guidance of $100-105 million, with a run rate below $100 million by Q4 2026, implies disciplined cost management. The company is adding capital sales representatives to drive NeuroStar system sales and investing in patient portal technology and AI-driven intake processes. These investments address the primary friction points in TMS adoption: physician awareness, patient access, and reimbursement complexity.

Operating cash flow guidance of negative $13 million to negative $17 million for the full year, with positive cash flow in the second half, represents an improvement from 2025's negative $20.4 million burn. Management expects Q1 2026 to be the highest burn quarter due to seasonality, with improvement thereafter. This phasing sets up a potential catalyst in Q3 2026 when positive cash flow is expected to become sustainable.

The COMP360 psilocybin collaboration represents a call option on the future of mental health treatment. COMPASS Pathways (CMPS) has completed two Phase 3 studies showing durable improvement after one or two doses, with an NDA submission expected and potential FDA decision by year-end. Greenbrook's existing REMS-compliant infrastructure for SPRAVATO positions it uniquely to commercialize COMP360 with minimal incremental investment. This provides a second growth driver beyond TMS, targeting the treatment-resistant depression population that already flows through Greenbrook clinics.

Risks and Asymmetries

Ongoing investigations by the U.S. Attorney's Office for the Middle District of Florida and the Michigan Attorney General into Greenbrook's pre-acquisition billing practices represent an immediate risk. While Neuronetics is cooperating fully and the practices occurred before its ownership, any finding of systematic issues could result in fines or reputational damage. Greenbrook now represents 59% of U.S. revenues, making any disruption to its operations material to the integrated strategy.

The planned transition of Greenbrook's largest supported physician groups out of the relationship by October 1, 2026, poses an execution risk. These groups likely represent a meaningful portion of referral volume, and failure to find suitable replacements could slow patient acquisition. The clinic segment's double-digit growth guidance assumes stable or expanding referral networks; any disruption would force a reset of expectations.

Reimbursement concentration remains a structural vulnerability. While NeuroStar enjoys broad coverage for adult MDD, the adolescent indication is still gaining payer adoption, and SPRAVATO reimbursement varies by state and payer. The company's optimization between billing models creates complexity that could lead to payment delays. The clinic segment's profitability depends on efficient revenue cycle management.

Patent expirations present a longer-term risk. Three U.S. patents expire in 2026, with additional patents expiring between 2026 and 2040. While regulatory clearances and clinical data provide protection, loss of patent coverage could enable lower-cost TMS competitors to enter the market, potentially pressuring system pricing.

On the upside, the adolescent market expansion offers meaningful asymmetry. If coverage expands to match adult MDD levels, the addressable market could increase by 30-40%, driving both device placements and clinic volumes. The BMP program's success—demonstrating 3x higher patient volumes—suggests that standardized protocols can unlock latent demand, potentially accelerating growth beyond current guidance.

Competitive Context and Positioning

Neuronetics competes in a fragmented but growing market. The global TMS market is projected to grow at 9.2% CAGR, driven by increasing TRD prevalence. Against direct TMS competitor BrainsWay, Neuronetics holds a market share advantage, with 2025 revenue of $149M versus BWAY's $52M, despite BWAY's higher gross margin (75% vs. 49%). This highlights STIM's strategic choice to prioritize scale and integration over near-term profitability.

BrainsWay's SWIFT Deep TMS protocol, which claims to reduce treatment time, represents a direct competitive threat. If SWIFT gains broader clinical acceptance, it could impact NeuroStar's volume growth. However, Neuronetics' larger installed base and extensive outcomes data create switching costs. The BMP program and Provider Connection initiatives build relationship-based moats that technology alone cannot easily displace.

Indirect competitors include LivaNova's VNS Therapy and Axsome's Auvelity. LivaNova's invasive approach carries surgical risks, limiting its addressable market to the most refractory patients. Axsome's oral medication offers convenience but cannot match TMS's non-systemic side effect profile. Neuronetics' positioning as a non-invasive, drug-free alternative with proven real-world effectiveness creates a distinct value proposition.

The key competitive differentiator is Neuronetics' vertical integration. While device competitors rely on third-party clinics for patient access, Neuronetics controls both the technology and the delivery channel. This enables faster protocol innovation and direct payer contracting. The Q4 cash flow inflection suggests Neuronetics is successfully managing the operational requirements of clinic management and referral development.

Valuation Context

Trading at $1.52 per share, Neuronetics carries a market capitalization of $105.3 million and an enterprise value of $167.5 million (1.12x revenue). This valuation stands in contrast to medtech peers. BrainsWay trades at 9.2x revenue, while LivaNova trades at 2.4x revenue with slower neuromodulation segment growth (7% vs. STIM's 15% pro forma). The valuation discount reflects investor skepticism about the integrated model's profitability and the overhang of legal investigations.

For an unprofitable growth company, the relevant metrics are revenue growth, gross margin trajectory, and the path to profitability. Neuronetics' 15% pro forma revenue growth compares favorably to peers, while its gross margin of 48.5% is improving sequentially. The Q4 operating cash flow of $0.9M suggests the business can fund its own operations within the next 12-18 months.

The cash position provides a runway. With $34.1M in total cash and guided operating cash burn of $13-17M in 2026, the company has sufficient liquidity to reach self-sustainability without dilutive equity raises. A $5M debt payment made in March 2026 saves $600K in annual interest expense, demonstrating a focus on optimizing the capital structure.

The valuation asymmetry is clear: if the integrated model achieves targets of double-digit clinic growth, positive second-half cash flow, and margin expansion toward 50%, the stock could re-rate toward medtech peer multiples of 2-3x revenue. If execution falters, the downside is supported by the company's net asset value and the standalone value of the NeuroStar device business.

Conclusion

Neuronetics stands at an inflection point where vertical integration is transitioning from a margin headwind to a growth and cash flow engine. The Greenbrook acquisition has created a national platform that generated $87M in clinic revenue with 28% pro forma growth while delivering operational improvements that resulted in positive Q4 operating cash flow. This validates the strategic thesis that controlling patient access and referral relationships provides significant value.

The investment case hinges on the sustainability of clinic segment growth and the resolution of legal overhang. The adolescent market expansion, BMP program success, and SPRAVATO rollout provide multiple drivers for sustained double-digit clinic growth, while operational leverage should drive margin expansion and cash generation in the second half of 2026. The legal investigations relate to pre-acquisition practices and have not impeded current operations.

At $1.52, the market values Neuronetics as a struggling device company rather than an integrated mental health platform. This creates an opportunity where successful execution of the integrated strategy could drive a re-rating, while the downside is protected by the NeuroStar technology and improving cash generation. For investors looking past near-term margin compression, STIM offers a combination of market leadership, multiple growth drivers, and a valuation that does not require perfection to deliver returns.